{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:11:36Z","timestamp":1751602296607,"version":"3.41.0"},"reference-count":32,"publisher":"EDP Sciences","issue":"4","license":[{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/www.edpsciences.org\/en\/authors\/copyright-and-licensing"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>Mettant fin \u00e0 une crise de l\u2019innovation dont la r\u00e9alit\u00e9 fait l\u2019objet de d\u00e9bats, les innovations pharmaceutiques r\u00e9centes, r\u00e9sultats d\u2019un encastrement de raisons scientifiques, industrielles, financi\u00e8res, politiques et \u00e9conomiques, aboutissent \u00e0 une diversification des portefeuilles de produits des industriels de la pharmacie au niveau mondial et \u00e0 un fort int\u00e9r\u00eat, de leur part, pour des produits dits de niche (th\u00e9rapies cibl\u00e9es, maladies rares, etc.). Ces nouvelles mol\u00e9cules sont mises sur le march\u00e9 \u00e0 des prix beaucoup plus \u00e9lev\u00e9s que par le pass\u00e9. En l\u2019absence d\u2019informations fiables sur les co\u00fbts support\u00e9s par les industriels, et sachant que des niveaux de marge tr\u00e8s \u00e9lev\u00e9s ont \u00e9t\u00e9 observ\u00e9s, ces prix suscitent des interrogations l\u00e9gitimes. Celles-ci sont \u00e9galement motiv\u00e9es par l\u2019absence de relation entre le prix et le b\u00e9n\u00e9fice th\u00e9rapeutique de ces nouvelles mol\u00e9cules. En France, face \u00e0 des niveaux de d\u00e9penses susceptibles de fragiliser la soutenabilit\u00e9 financi\u00e8re du syst\u00e8me de protection sociale, les autorit\u00e9s publiques ont jusqu\u2019\u00e0 pr\u00e9sent toujours privil\u00e9gi\u00e9 des interventions sur les prix ou les conditions et volumes de remboursement, conformes aux modes de r\u00e9gulation existants. D\u2019autres modes de r\u00e9gulation (recours \u00e0 la licence d\u2019office, achat group\u00e9, etc.) pourraient dans le futur \u00eatre employ\u00e9s dans un souci croissant d\u2019efficience des d\u00e9penses publiques. Les difficult\u00e9s rencontr\u00e9es pour r\u00e9guler un secteur industriel profond\u00e9ment transform\u00e9, appellent \u00e0 une r\u00e9forme des syst\u00e8mes d\u2019\u00e9valuation et de r\u00e9gulation nationaux.<\/jats:p>","DOI":"10.1051\/medsci\/20183404017","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T07:52:15Z","timestamp":1523865135000},"page":"354-361","source":"Crossref","is-referenced-by-count":3,"title":["Pourquoi les nouveaux m\u00e9dicaments sont-ils si chers ?"],"prefix":"10.1051","volume":"34","author":[{"given":"Catherine","family":"Le Gal\u00e8s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"250","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"key":"R1","unstructured":"cour des comptes. L\u2019avenir de l\u2019assurance maladie. Rapport public th\u00e9matique. Paris, 2017."},{"key":"R2","unstructured":"cour des comptes. La fixation du prix des m\u00e9dicaments : des r\u00e9sultats significatifs, des enjeux toujours majeurs d\u2019efficience et de soutenabilit\u00e9, un cadre d\u2019action \u00e0 fortement r\u00e9\u00e9quilibrer. Rapport sur l\u2019application des lois de Financement de la S\u00e9curit\u00e9 Sociale. Paris, 2017."},{"key":"R3","doi-asserted-by":"crossref","first-page":"e1002032","DOI":"10.1371\/journal.pmed.1002032","volume":"13","author":"Iyengar","year":"2016","journal-title":"PLoS Med"},{"key":"R4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"R5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2961","volume":"8","author":"Munos","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"R6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.3.1","volume":"3","author":"Hall","year":"2014","journal-title":"Intractable Rare Dis Res 2014"},{"key":"R8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"R9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.healthpol.2010.12.002","volume":"100","author":"Morgan","year":"2011","journal-title":"Health Policy"},{"key":"R10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bmj.e4348","volume":"345","author":"Light","year":"2012","journal-title":"BMJ"},{"key":"R11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/cid\/ciu012","volume":"58","author":"Hill","year":"2014","journal-title":"Clin infect dis"},{"key":"R12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/icc\/dtt023","volume":"22","author":"Montalban","year":"2013","journal-title":"Industrial and Corporate Change"},{"key":"R13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.drudis.2014.03.018","volume":"19","author":"Kinch","year":"2014","journal-title":"Drug Discov Today"},{"key":"R14","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jval.2012.09.004","volume":"15","author":"C\u00f4t\u00e9","year":"2012","journal-title":"Value in Health"},{"key":"R15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1257\/jep.29.1.139","volume":"29","author":"Howard","year":"2015","journal-title":"J Econ Perspect"},{"key":"R16","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1051\/medsci\/20173312017","volume":"33","author":"Franc","year":"2017","journal-title":"Med Sci (Paris)"},{"key":"R17","unstructured":"Comptes de la sant\u00e9. Les d\u00e9penses de sant\u00e9 en 2015. DREES, Minist\u00e8re de la Sant\u00e9, 2016."},{"key":"R18","unstructured":"Danzon PM, Keuffel EL. Regulation of the pharmaceutical-biotechnology industry. In : Economic regulation and its reform: what have we learned?. Chicago : University of Chicago Press, 2014 : 407-84."},{"key":"R19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacbts.2016.06.003","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"R20","unstructured":"Bensadon AC, Marie E, Morelle A. Rapport sur la pharmacovigilance et gouvernance de la cha\u00eene du m\u00e9dicament. Inspection g\u00e9n\u00e9rale des affaires sociales (IGAS). Paris, 2011."},{"key":"R21","unstructured":"Polton D. Rapport sur la r\u00e9forme des modalit\u00e9s d\u2019\u00e9valuation des m\u00e9dicaments. Minist\u00e8re de la Sant\u00e9 et des Affaires Sociales. Paris, 2015."},{"key":"R22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1051\/medsci\/20183401018","volume":"34","author":"Le Gal\u00e8s","year":"2018","journal-title":"Med Sci (Paris)"},{"key":"R23","unstructured":"Accord cadre du 31\/12\/2015 entre le Comit\u00e9 \u00e9conomique des produits de sant\u00e9 et les entreprises du m\u00e9dicament. Paris, 2015."},{"key":"R24","unstructured":"Lettre d\u2019orientation des ministres. Minist\u00e8re des Finances et des Comptes publics, Minist\u00e8re des Affaires Sociales et de la Sant\u00e9, et Minist\u00e8re de l\u2019Economie. Paris, 2017."},{"key":"R25","unstructured":"Drug safety: FDA expedited many applications, but data for post-approval oversight need improvement. US Government Accountability Office, 2015."},{"key":"R26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/medlaw\/fwu005","volume":"22","author":"Gibson","year":"2014","journal-title":"Med Law Rev"},{"key":"R27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1377\/hlthaff.2014.0122","volume":"33","author":"Frank","year":"2014","journal-title":"Health Affairs"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Vandenbroeck P, Raeymakers P, Wickert R, et al. Future scenarios about drug development and drug pricing. Brussels: Belgian Health Care Knowledge Centre (KCE), 2016.","DOI":"10.57598\/R271C"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Greffion J, Breda T. Fa\u00e7onner la prescription, influencer les m\u00e9decins. Les effets difficilement saisissables du c\u0153ur de m\u00e9tier des grandes entreprises pharmaceutiques. Revue de la R\u00e9gulation 2015; 17.","DOI":"10.4000\/regulation.11272"},{"key":"R30","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1371\/journal.pmed.0030191","volume":"3","author":"Moynihan","year":"2006","journal-title":"PLoS Med"},{"key":"R31","unstructured":"Galbraith JK. The affluent society. Nova York : New American Library, 1958."},{"issue":"hs2","key":"R32","first-page":"1","volume":"30","author":"ITMO","year":"2014","journal-title":"Med Sci (Paris)"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.medecinesciences.org\/10.1051\/medsci\/20183404017\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:53:52Z","timestamp":1751565232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medecinesciences.org\/10.1051\/medsci\/20183404017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":32,"journal-issue":{"issue":"4"},"alternative-id":["medsci2018344p354"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/20183404017","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"type":"print","value":"0767-0974"},{"type":"electronic","value":"1958-5381"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}